221 related articles for article (PubMed ID: 34840975)
1. The Significance of Autoantibodies in Juvenile Dermatomyositis.
Kwiatkowska D; Reich A
Biomed Res Int; 2021; 2021():5513544. PubMed ID: 34840975
[TBL] [Abstract][Full Text] [Related]
2. Myositis autoantibodies.
Casciola-Rosen L; Mammen AL
Curr Opin Rheumatol; 2012 Nov; 24(6):602-8. PubMed ID: 22955022
[TBL] [Abstract][Full Text] [Related]
3. Dermatomyositis Clinical and Pathological Phenotypes Associated with Myositis-Specific Autoantibodies.
Wolstencroft PW; Fiorentino DF
Curr Rheumatol Rep; 2018 Apr; 20(5):28. PubMed ID: 29637414
[TBL] [Abstract][Full Text] [Related]
4. Muscle Biopsy Findings in Combination With Myositis-Specific Autoantibodies Aid Prediction of Outcomes in Juvenile Dermatomyositis.
Deakin CT; Yasin SA; Simou S; Arnold KA; Tansley SL; Betteridge ZE; McHugh NJ; Varsani H; Holton JL; Jacques TS; Pilkington CA; Nistala K; Wedderburn LR;
Arthritis Rheumatol; 2016 Nov; 68(11):2806-2816. PubMed ID: 27214289
[TBL] [Abstract][Full Text] [Related]
5. [Dermatomyositis: new antibody, new classification].
Bolko L; Gitiaux C; Allenbach Y
Med Sci (Paris); 2019 Nov; 35 Hors série n° 2():18-23. PubMed ID: 31859626
[TBL] [Abstract][Full Text] [Related]
6. Two cases with autoantibodies to small ubiquitin-like modifier activating enzyme: A potential unique subset of dermatomyositis-associated interstitial lung disease.
Gono T; Tanino Y; Nishikawa A; Kawamata T; Hirai K; Okazaki Y; Shibata Y; Kuwana M
Int J Rheum Dis; 2019 Aug; 22(8):1582-1586. PubMed ID: 31050194
[TBL] [Abstract][Full Text] [Related]
7. Recent advances in dermatomyositis-specific autoantibodies.
Fujimoto M; Watanabe R; Ishitsuka Y; Okiyama N
Curr Opin Rheumatol; 2016 Nov; 28(6):636-44. PubMed ID: 27533321
[TBL] [Abstract][Full Text] [Related]
8. Distinct tissue injury patterns in juvenile dermatomyositis auto-antibody subgroups.
Nguyen M; Do V; Yell PC; Jo C; Liu J; Burns DK; Wright T; Cai C
Acta Neuropathol Commun; 2020 Aug; 8(1):125. PubMed ID: 32758284
[TBL] [Abstract][Full Text] [Related]
9. Clinical significance of autoantibodies in dermatomyositis and systemic sclerosis.
Tartar DM; Chung L; Fiorentino DF
Clin Dermatol; 2018; 36(4):508-524. PubMed ID: 30047434
[TBL] [Abstract][Full Text] [Related]
10. Myositis-specific autoantibodies in Japanese patients with juvenile idiopathic inflammatory myopathies.
Ueki M; Kobayashi I; Takezaki S; Tozawa Y; Okura Y; Yamada M; Kuwana M; Ariga T
Mod Rheumatol; 2019 Mar; 29(2):351-356. PubMed ID: 29532710
[TBL] [Abstract][Full Text] [Related]
11. [Myositis-specific autoantibodies and their clinical significance].
Suzuki S
Brain Nerve; 2011 Nov; 63(11):1197-203. PubMed ID: 22068472
[TBL] [Abstract][Full Text] [Related]
12. Specific autoantibodies in dermatomyositis: a helpful tool to classify different clinical subsets.
Merlo G; Clapasson A; Cozzani E; Sanna L; Pesce G; Bagnasco M; Burlando M; Parodi A
Arch Dermatol Res; 2017 Mar; 309(2):87-95. PubMed ID: 27928683
[TBL] [Abstract][Full Text] [Related]
13. [Dermatomyositis and Autoantibodies].
Fujimoto M
Brain Nerve; 2018 Apr; 70(4):427-438. PubMed ID: 29632290
[TBL] [Abstract][Full Text] [Related]
14. Distinctive cutaneous and systemic features associated with specific antimyositis antibodies in adults with dermatomyositis: a prospective multicentric study of 117 patients.
Best M; Jachiet M; Molinari N; Manna F; Girard C; Pallure V; Cosnes A; Lipsker D; Hubiche T; Schmutz JL; Le Corre Y; Cordel N; Dandurand M; Dereure O; Guillot B; Du-Thanh A; Bulai Livideanu C; Chasset F; Bouaziz JD; Francès C; Bengoufa D; Vincent T; Bessis D;
J Eur Acad Dermatol Venereol; 2018 Jul; 32(7):1164-1172. PubMed ID: 29237090
[TBL] [Abstract][Full Text] [Related]
15. Anti-MDA5 autoantibodies associated with juvenile dermatomyositis constitute a distinct phenotype in North America.
Mamyrova G; Kishi T; Shi M; Targoff IN; Huber AM; Curiel RV; Miller FW; Rider LG;
Rheumatology (Oxford); 2021 Apr; 60(4):1839-1849. PubMed ID: 33140079
[TBL] [Abstract][Full Text] [Related]
16. Two young-adult female cases of dermatomyositis with antibodies for transcriptional intermediary factor 1-γ.
Matsuura E; Ishiguro N; Katsumata Y; Urano W; Yamanaka H; Kondo M; Kuwana M; Kaji K; Hamaguchi Y; Fujimoto M; Kawashima M
Eur J Dermatol; 2012; 22(5):668-71. PubMed ID: 22992252
[TBL] [Abstract][Full Text] [Related]
17. Autoantibodies in children with juvenile dermatomyositis: A single centre experience from North-West India.
Hussain A; Rawat A; Jindal AK; Gupta A; Singh S
Rheumatol Int; 2017 May; 37(5):807-812. PubMed ID: 28331982
[TBL] [Abstract][Full Text] [Related]
18. Anti-melanoma differentiation-associated protein 5-associated dermatomyositis: expanding the clinical spectrum.
Hall JC; Casciola-Rosen L; Samedy LA; Werner J; Owoyemi K; Danoff SK; Christopher-Stine L
Arthritis Care Res (Hoboken); 2013 Aug; 65(8):1307-15. PubMed ID: 23436757
[TBL] [Abstract][Full Text] [Related]
19. [Dermatomyositis associated with anti-MDA5 autoantibody].
Collado MV; Gargiulo MLÁ; Gómez R; Gómez G; Pérez N; Suarez L; Taratuto AL; Aruj P
Medicina (B Aires); 2018; 78(5):360-363. PubMed ID: 30285929
[TBL] [Abstract][Full Text] [Related]
20. The clinical spectrum of dermatomyositis and the new autoantibodies - with regard to two clinical cases with distinct associations.
Calvão da Silva JCM; Santiago L; Brites MM; Gonçalo M
Australas J Dermatol; 2020 May; 61(2):e241-e243. PubMed ID: 31881093
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
